Ribociclib in combination with other drugs
Showing 1 - 25 of >10,000
A 52-week Post-marketing, Observational Study to Confirm Safety
Completed
- Hypercholesterolemia
- +2 more
- Ezetimibe
- Ezetimibe + other lipid-lowering medication(s)
- (no location specified)
Feb 7, 2022
A 12-week Post-marketing, Observational Study to Confirm Safety
Completed
- Hypercholesterolemia
- +2 more
- Ezetimibe
- Ezetimibe + other lipid-lowering medication(s)
- (no location specified)
Feb 7, 2022
Metastatic Malignant Solid Tumor, Metastatic NUT Carcinoma, Unresectable Malignant Solid Tumor Trial (Abemaciclib, BET
Suspended
- Metastatic Malignant Solid Neoplasm
- +3 more
- Abemaciclib
- +3 more
-
Boston, MassachusettsDana-Farber - Harvard Cancer Center LAO
Sep 17, 2022
Cytoflavin in Combination With Reperfusion in Stroke Patients
Not yet recruiting
- Acute Stroke
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
- Control
- (no location specified)
Apr 4, 2022
Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality
Recruiting
- Breast Cancer Stage IV
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
-
Mansoura, Dakahlia, EgyptOncology center mansoura university
Jan 1, 2023
Breast Cancer, Metastatic Breast Cancer Trial (Elacestrant, Alpelisib, Everolimus)
Not yet recruiting
- Breast Cancer
- Metastatic Breast Cancer
- Elacestrant
- +4 more
- (no location specified)
Sep 28, 2022
Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer
Terminated
- Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
- +2 more
- Ribociclib
- +2 more
-
Boston, Massachusetts
- +2 more
Mar 16, 2022
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)
Recruiting
- Non Hodgkins Lymphoma
- Diffuse Large B-cell Lymphoma
- tafasitamab
- +3 more
-
Aichi, Japan
- +4 more
Jan 24, 2022
Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy
Recruiting
- Advanced Breast Cancer
- The combination of Dalpiciclib with physician-selected endocrine therapy
- Chemotherapy selected by the physician
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
HIV Trial in United States (Abacavir sulfate, Lamivudine, Stavudine)
Completed
- HIV Infections
- Abacavir sulfate
- +4 more
-
Los Angeles, California
- +6 more
Oct 27, 2021
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)
Recruiting
- Metastatic Breast Cancer
- Recurrent Ovarian Carcinoma
-
Salt Lake City, Utah
- +1 more
May 3, 2022
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma Trial in Portland (Doxorubicin
Active, not recruiting
- Advanced Soft Tissue Sarcoma
- +26 more
- Doxorubicin Hydrochloride
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Jan 6, 2023
Risarg® Combined With Endocrine Therapy or Chemotherapy in
Not yet recruiting
- HR+HER2- Advanced Breast Cancer
- Ribociclib
- Combination chemotherapy
- (no location specified)
Nov 20, 2023
Glioblastoma Multiforme, Glioma of Brain Trial in Chandler, Phoenix, Scottsdale (Ribociclib, Everolimus)
Completed
- Glioblastoma Multiforme
- Glioma of Brain
-
Chandler, Arizona
- +2 more
Jan 11, 2023
Breast Cancer Trial in Worldwide (Docetaxel / Capecitabine, Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine)
Active, not recruiting
- Breast Cancer
- Docetaxel / Capecitabine
- +5 more
-
Cairo, Egypt
- +51 more
Oct 24, 2022
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
Cancer, Tumors, Tumor Trial in Netherlands (Panitumumab, Olaparib, Dabrafenib)
Recruiting
- Cancer
- +3 more
- Panitumumab
- +32 more
-
Amersfoort, Utrecht, Netherlands
- +34 more
Oct 26, 2021
Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)
Terminated
- Lymphoma
- Solid Neoplasm
- Gemcitabine Hydrochloride
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)
Recruiting
- Triple Negative Breast Cancer
-
Chicago, Illinois
- +5 more
Oct 31, 2022
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in United
Recruiting
- Hormone-Resistant Prostate Cancer
- +3 more
-
Ann Arbor, Michigan
- +3 more
Feb 2, 2023